Ricerca avanzata

Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2016 Agosto;35(4) > International Angiology 2016 Agosto;35(4):369-73

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOINTERNATIONAL ANGIOLOGY

Rivista di Angiologia

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899

Periodicità: Bimestrale

ISSN 0392-9590

Online ISSN 1827-1839

 

International Angiology 2016 Agosto;35(4):369-73

 REVIEWS

Do we have to anticoagulate patients with cerebral venous thrombosis?

Gergely FEHER 1, Zsolt ILLES 2, David HARGROVES 3, Samuel KOMOLY 4

1 Szigetvar Hospital, Szigetvár, Hungary; 2 University of Southern Denmark, Odense, Denmark; 3 William Harvey Hospital, Kent, UK; 4 University of Pecs, Pécs, Hungary

Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events. We have identified 15 follow-up studies studies with 2422 patients. The mean duration of follow-up was 37.9 months. Death occured in 6.5% and 76.4% of the patients had favorable outcome; 85.5% received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82.1% received long-term anticoagulation. Recurent CVT occured in 3.7% and other thrombotic event occured in 5.4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation. The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina